Cardiovascular disease (CVD) and cancer are two major causes of mortality worldwide (1). Chemotherapeutic agents have come a long way and the advent of targeted therapies has ushered in a new era of personalised cancer care which, along with risk factor reduction, have shown a decline in cancer mortality (2, 3). As cancer survival improves, the burden of CVD becomes more apparent (4). The Surveillance, Epidemiology and End Results (SEER) database showed that the risk of mortality from CVD was greatest in the first year of cancer diagnosis and patients diagnosed under 55 years old had a ten-fold risk of CVD related death compared to the general population (5).
Author Sub-editor: Dr May Hu Dr May Hu is a cardiology trainee in the North West deanery. She graduated with First Class Honours from the University
Author Sub-editor: Dr Jhiamluka Solano Dr Jhiamluka Solano is a cardiology resident doctor (ST6) in the Yorkshire and Humber Deanery, currently undertaking a DPhil (PhD)
Author Sub-editor: Dr Justin Chiong Dr Justin Chiong is an NIHR Academic Clinical Fellow and Cardiology Registrar in the North West Deanery. He graduated from
Author Heartbeat Sub-Editor: Marina Zafeiri Dr Marina Zafeiri is an IMT3 in the Wessex deanery, with a strong interest in Cardiology. She graduated from Athens
Author Heartbeat Sub-Editor: Toby MacCarthy Author: Toby MacCarthy
Author Heartbeat Sub-Editor: Toby MacCarthy Author: Toby MacCarthy
